Diagnosis Of Parkinsons Via Datscan And Clinical Exam Are Similarly Accurate
Despite the DaTscan being available to help diagnose Parkinsons, in most clinical situations, a DaTscan will not add information to what can be gleaned from the clinical exam. One study actually demonstrated that the accuracy of diagnosis in early PD was the same whether the diagnosis was reached using clinical exam or using DaTscan.
How Many Canadians Live With Parkinsonism And How Many Are Newly Diagnosed Each Year
Based on the latest estimates available , in 20132014, approximately 84,000 Canadians aged 40 years and older were living with diagnosed parkinsonism and 10,000 Canadians were newly diagnosed with this condition . The age-standardized prevalence was 1.5Footnote i times higher among males than among females , and similarly the age-standardized incidence was 1.7Footnote i times higher among males than females . The epidemiological burden of parkinsonism increases with age. In 20132014, when comparing estimates among Canadians aged 85 years and older vs. those aged 40-44 years, the prevalence of the condition was 169Footnote i times higher in the older age group , while the incidence was 48Footnote i times higher in the older age group .
Figure 1: Prevalence of diagnosed parkinsonism, including Parkinsons disease, by sex and age group, Canada, 20132014
| Age group |
|---|
| 44.7 | 55.1 |
Note: The 95% confidence interval shows an estimated range of values which is likely to include the true value 19 times out of 20. Data source: Public Health Agency of Canada, using Canadian Chronic Disease Surveillance System data files contributed by provinces and territories, July 2017.
What Do The Results Mean
The take-home message here is that “sniff tests” may be able to predict a person’s risk of developing Parkinson’s disease. That said, there are a few caveats to keep in mind.
One is that a loss of smell can be due to other health problems besides Parkinson’s. Other neurological diseases like Alzheimer’s can cause smell disturbances, as can non-neurological conditions like chronic rhinosinusitis. This is why devising a smell test that is specific for PD is important, and researchers have not yet sorted this all out.
Secondly, “smell tests” must test for the correct smell disturbance. Simply saying a person has a loss of smell is rather vague. Perhaps one person has a hard time discriminating between odors while another cannot identify odors. Or a person may have a higher threshold for detecting odors.
With that, research suggests that in Parkinson’s, there is a favorable decline in odor identification, rather than odor detection, meaning they can “smell it,” but not say what it is.
Lastly, it’s critical to remember that a link or association is simply a connection or a finding based on statisticsit’s not 100 percent predictive of any one individual. In other words, a person could lose their sense of smell and never develop Parkinson’s disease. Likewise, there are people with Parkinson’s disease who retain their sense of smell.
Read Also: What Are Early Warning Signs Of Parkinson’s Disease
What Are The Pitfalls Of Datscan
DaTscan will appear abnormal in any disease in which there is a loss of dopamine nerve endings in the striatum. Therefore, Parkinson-plus syndromes, discussed in a prior blog, such as Progressive supranuclear palsy , Corticobasal ganglionic degeneration and Multiple system atrophy all typically demonstrate abnormal DaTscans. DaTscan therefore cannot be used to distinguish between these syndromes.
Every medical test has a false positive and a false negative rate. This means, that it is inevitable that in a certain percentage of people who have PD, the DaTscan will be read as normal and in a certain percentage of people without PD, the DaTscan will be read as abnormal. Results of any medical test that is performed, must therefore be considered within the entire clinical context.
Genetic Testing For Parkinson’s Disease And Related Disorders Minutes
Dr. Michael WatsonAlthough the terms are often used interchangeably, testing and screening have two distinct uses. Genetic testing involves the analysis of symptomatic individuals or those with a family history, whereas screening uses a population-based approach. Ethical issues associated with both of these forms of testing include test validation and test performance. The intended use of the test should be specific it might therefore be helpful to articulate the intended use as if FDA approval were required.
There are 2 stages through which a genetic test can be translated into clinical practice.
Stage 1: includes population-based research to establish scientific links between genes and diseases. Laboratories would not have to be approved under the Clinical Laboratory Improvement Amendments of 1988 because they do not report to the families, but Institutional Review Boards should oversee patient involvement. The FDA regulates manufactured devices and drugs, and provides guidance for informed consent requirements, but genetic “home brew” tests often fall through the regulatory gap. Moreover, while CLIA regulates how laboratories practice, it does not address the issue of clinical validity.
Stage 3: involves the development of practice standards for tests that are found to be adequate and of utility at Stage 2. This involves the development of guidelines for testing and who should be tested.
Dr. Quaid outlined the types of genetic testing as:
Don’t Miss: Advanced Parkinson’s Disease Life Expectancy
Thanks For Signing Up
We are proud to have you as a part of our community. To ensure you receive the latest Parkinsons news, research updates and more, please check your email for a message from us. If you do not see our email, it may be in your spam folder. Just mark as not spam and you should receive our emails as expected.
How Is Parkinson’s Diagnosed
Current evidence suggests that Parkinsons tends to develop gradually. It may be many months, even years, before the symptoms become obvious enough for someone to go to the doctor.
This information looks at what parkinsonism is, how Parkinsons and other similar conditions may be diagnosed, and explains some of the tests that may be involved in the process.
Parkinsonism is a term used to describe symptoms or signs that are found in Parkinsons, but which can also be found in other conditions that cause slowness of movement, stiffness and tremor.
Most people with a form of parkinsonism have idiopathic Parkinsons disease, also known as Parkinsons. Idiopathic means the cause is unknown.
Other less common forms of parkinsonism include multiple system atrophy , progressive supranuclear palsy , drug-induced parkinsonism and vascular Parkinsons.
If youre concerned about symptoms youve been experiencing, you should visit your GP. If your GP suspects you have Parkinsons, clinical guidelines recommend they should refer you quickly to a specialist with experience in diagnosing the condition .
Its not always easy to diagnose the condition. So its important that you see a Parkinsons specialist to get an accurate diagnosis and to consider the best treatment options.
Diagnosing Parkinsons can take some time as there are other conditions, such as essential tremor , with similar symptoms. There is also currently no definitive test for diagnosing Parkinsons.
Don’t Miss: Essential Oils For Parkinson
Gauging Speed Of Movement
Bradykinesia occurs in most people who have Parkinson’s. It may cause a lack of spontaneous facial expression and fewer eye blinks per minute than usual, and your doctor will look for these signs in your physical exam.
Your doctor also may assess your speed of movement by asking you to open and close each hand or tap your index finger against your thumb repeatedly, making large movements as quickly as possible. In people with Parkinson’s disease, the movement may start off fast and precise, but it will deteriorate quickly, becoming slow and limited.
Gait is also another way to test for this. Observing a patient while they walk, noting the length of their stride as well as the speed at which they move, can tell doctors quite a bit. Lack of arm swing is also a feature that appears fairly early in those with Parkinson’s.
Parkinson’s Disease Is A Movement Disorder
Parkinson’s disease is a movement disorder that is degenerative and chronic, and symptoms continue and generally worsen over time. The National Institute of Neurological Disorders and Stroke estimates about 50,000 people are diagnosed with PD each year in the U.S. The cause of PD is unknown. There is currently no cure, but there are several treatment options available to manage symptoms including medications and surgery.
Don’t Miss: What Is The Life Expectancy Of Someone With Parkinson’s Disease
Parkinson’s Disease Is Only Seen In People Of Advanced Age
Parkinson’s disease isn’t just seen in people of advanced age. While it does tend to affect people over age 60 more often, in about 5% to 10% of cases, “early onset” PD can begin in people as young as age 40. The progression of PD is different for everyone, however, those who develop it at earlier ages seem to have a more severe progression. Life expectancy for people with Parkinson’s disease is about the same as the average population, but complications from the disease in the later stages can lead to fatal outcomes from choking, pneumonia, and falling.
Who Are More Likely To Develop Parkinson’s Disease
Parkinson’s disease affects both men and women, though about 50% more men are affected than women. The reasons for this are unclear but there are theories that estrogen may cause women to develop the disease less frequently, and when they do, they seem to get a milder form of it. The National Institute of Neurological Disorders and Stroke estimates about 50,000 people are diagnosed with PD each year in the U.S. However, this number may be higher due to the fact that many people in the early stages of PD assume their symptoms are due to aging and do not seek medical attention. Complicating the diagnosis is that symptoms of Parkinson’s resemble other diseases and there is no one definitive test to diagnose it.
Recommended Reading: What Are The Four Cardinal Signs Of Parkinson’s Disease
What Tests Diagnose Parkinson’s Disease
There currently are no tests that can definitively diagnose Parkinsons Disease. A diagnosis is based on the clinical findings of your physician in combination with your report on the symptoms you are experiencing.
In situations where an older person presents with the typical features of Parkinsons and they are responsive to dopamine replacement therapy, there is unlikely to be any benefit to further investigation or imaging.
Dementia With Lewy Bodies
DLB is characterized by the early development of cognitive symptoms and psychotic symptoms such as hallucinations. Parkinsonian motor symptoms occur later in the progression of the disease. After Alzheimers, DLB is the leading cause of dementia. DLB typically does not occur before the age of 65. In DLB, alpha synuclein protein builds up throughout the cerebral cortex of the brain, forming collections called Lewy bodies.
DLB is often misdiagnosed as Alzheimers. Symptoms of DLB may respond to medications for Parkinsons or Alzheimers, but certain Alzheimers medications carry high risk for dangerous side effects if given to those with DLB. DLB and Parkinsons disease dementia have many features in common, and together they are known as the Lewy body dementias.
Read Also: What Essential Oils Are Good For Parkinson’s Disease
What Is The Trend Over Time In The Prevalence And Incidence Of Parkinsonism In Canada
Between 20042005 and 20132014, the number of Canadians living with diagnosed parkinsonism increased from approximately 61,000 to 84,000, while the number of Canadians newly diagnosed increased from approximately 8,000 to 10,000. However, during the same period, there was no significant change in the age-standardized prevalence proportion, which remained at 0.4%, or the incidence rate, which went from 51.6 per 100,000 to 52.6 per 100,000. The sex differential also remained constant over time for both indicators .
Figure 3: Age-standardized prevalence and incidence of diagnosed parkinsonism, including Parkinsons disease, among Canadians aged 40 years and older, by sex, 20042005 to 20132014
| Indicator | |
|---|---|
| 67.8 | 40.3 |
Notes: Age-standardized estimates to the 2011 Canadian population. The 95% confidence interval shows an estimated range of values which is likely to include the true value 19 times out of 20. The 95% confidence intervals of the prevalence estimates are too small to be illustrated.Data source: Public Health Agency of Canada, using Canadian Chronic Disease Surveillance System data files contributed by provinces and territories, July 2017.
Causes Of Early Onset Parkinsons Disease
Its unclear exactly what causes Parkinsons at any age. Genetic factors, environmental factors, or some combination of the two may play a role. This condition occurs when cells are lost in the part of the brain that produces dopamine. Dopamine is responsible for sending brain signals that control movement.
Certain genes are associated with early onset Parkinsons.
According to the National Parkinson Foundation, studies show that 65 percent of people with Parkinsons who experience onset before age 20 may do so because of a genetic mutation. This organization also suggests this mutation affects 32 percent of people who experience onset between age 20 and 30.
Environmental causes of the condition may include exposure to chemical toxins such as certain insecticides, fungicides, and herbicides.
The U.S. Department of Veterans Affairs recognizes Parkinsons as a disease caused by exposure to Agent Orange. Agent Orange is a synthetic chemical herbicide that was used to spray vegetation and trees during the Vietnam War.
You may have a higher risk of developing Parkinsons if you:
- are a man
Recommended Reading: Yopd Life Expectancy
Further Testing In Parkinson’s
In other situations, where perhaps the diagnosis is not as clear, younger individuals are affected, or there are atypical symptoms such as tremor affecting both hands or perhaps no tremor at all, further testing may help. For example, imaging can play a role in differentiating between essential tremor and Parkinsons. It can also be important to confirm what is initially a clinical diagnosis of Parkinsons prior to an invasive treatment procedure such as surgical DBS
Parkinson’s Disease Can Be Prevented
There does not seem to be a way to predict or prevent Parkinson’s disease. Current research is investigating a biomarker â some kind of biological abnormality that would be present in patients with PD â that would be able to be detected from testing. This could help doctors identify people who are at-risk for developing Parkinson’s and thus find treatments to stop the disease process in the early stages or slow the progression. There are rare cases of genetically inherited PD where researchers can test for these genetic biomarkers to determine a person’s risk for developing the disease.
Don’t Miss: Can Alcoholism Mimic Parkinson’s
When Is Datscan Helpful
There are situations in which DaTscan can be very helpful in securing a diagnosis when neurologic exam findings are not clear-cut. Although DaTscan cannot distinguish PSP, CBGD, and MSA from PD, studies suggest that it may be able to distinguish drug-induced parkinsonism and vascular parkinsonism from PD.
The FDA indication for DaTscan is for distinguishing between PD and essential tremor . Usually it is quite straightforward for a neurologist to distinguish between the tremors of ET and the tremors of PD. PD tremors occur at rest and are accompanied by slowness and stiffness of the limb, whereas ET tremors occur with action and are not accompanied by slowness and stiffness of the limb. However, some people may have mixed tremor features making the diagnosis more difficult. In those cases, a DaTscan can be very useful.
How Is Parkinson’s Disease Diagnosed
Your doctor will ask questions about your symptoms and your past health and will do a neurological exam. This exam includes questions and tests that show how well your nerves are working. For example, your doctor will watch how you move. He or she will check your muscle strength and reflexes and will check your vision.
Your doctor also may check your sense of smell and ask you questions about your mood.
In some cases, your doctor will have you try a medicine for Parkinson’s disease. If that medicine helps your symptoms, it may help the doctor find out if you have the disease.
Tests
There are no lab or blood tests that can help your doctor know whether you have Parkinson’s. But you may have tests to help your doctor rule out other diseases that could be causing your symptoms. For example:
- An MRI or CT scan is used to look for signs of a stroke or brain tumor.
- Blood tests check for abnormal thyroid hormone levels or liver damage.
Another type of imaging test, called PET, sometimes may detect low levels of dopamine in the brain. These low levels are a key feature of Parkinson’s. But PET scanning isn’t commonly used to evaluate Parkinson’s. That’s because it’s very expensive, not available in many hospitals, and only used experimentally.
Read Also: Did Disease Symptoms
Gait & Balance Abnormalities
Parkinsons Disease Exam
Patients with Parkinsons disease can develop an alteration of the postural reflexes that causes instability in gait and balance control. Such alterations usually develop later in the course of the illness and are a major cause of disability, especially because of the high risk for falls that derives.
Using the exam to pick up postural instability is of the utmost importance for the management of patients with PD, since it will trigger either a medication adjustment or a physical therapy intervention both aimed at falls prevention.
We have three tests for this part of the PD exam:
1) Standing up from a chair
2) Free walking
3) Provoked pull test maneuver for balance
Clinical Basis Of The Levodopa Test
Parkinsons disease is difficult to diagnose, especially in the early stages. Several neurological diseases such as atypical Parkinsonian disorders show similar symptoms to Parkinsons disease, but have different causes. There is no single test that can definitively identify Parkinsons disease, and 5 to 10 percent of patients are misdiagnosed. Up to 20 percent of patients who are diagnosed with Parkinsons disease are later found to have other conditions.
Parkinsons disease is characterized by low levels of a neurotransmitter called dopamine in the brain. This is caused by the death of dopaminergic neurons in a region of the brain called the substantia nigra, which regulates motor functions and normal physical activity. This causes progressive deterioration of motor functions in Parkinsons disease patients resulting in typical motor symptoms .
Levodopa is the precursor of dopamine that, unlike dopamine, can cross the blood-brain barrier. Once inside the brain, it is converted into dopamine by the enzyme, dopa decarboxylase and replenishes dopamine levels, thereby restoring or improving motor function. That is why patient response to levodopa can be used to distinguish Parkinsons disease from other neurological conditions.
You May Like: Jamie Foxx Parkinson’s